It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive Schwann cell-derived neoplasms that occur sporadically or in patients with neurofibromatosis type 1 (NF1). Preclinical research on sporadic MPNSTs has been limited as few cell lines exist. We generated and characterized a new sporadic MPNST cell line, 2XSB, which shares the molecular and genomic features of the parent tumor. These cells have a highly complex karyotype with extensive chromothripsis. 2XSB cells show robust invasive 3-dimensional and clonogenic culture capability and form solid tumors when xenografted into immunodeficient mice. High-density single nucleotide polymorphism array and whole exome sequencing analyses indicate that, unlike NF1-associated MPNSTs, 2XSB cells have intact, functional NF1 alleles with no evidence of mutations in genes encoding components of Polycomb Repressor Complex 2. However, mutations in other genes implicated in MPNST pathogenesis were identified in 2XSB cells including homozygous deletion of CDKN2A and mutations in TP53 and PTEN. We also identified mutations in genes not previously associated with MPNSTs but associated with the pathogenesis of other human cancers. These include DNMT1, NUMA1, NTRK1, PDE11A, CSMD3, LRP5 and ACTL9. This sporadic MPNST-derived cell line provides a useful tool for investigating the biology and potential treatment regimens for sporadic MPNSTs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Medical University of South Carolina, Department of Pathology and Laboratory Medicine, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475)
2 University of Alabama at Birmingham, Department of Pathology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Medical Scientist Training Program, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); Children’s Hospital of Philadelphia, Division of Neurology, Philadelphia, USA (GRID:grid.239552.a) (ISNI:0000 0001 0680 8770)
3 Medical University of South Carolina, Department of Pathology and Laboratory Medicine, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475); Medical University of South Carolina, Center for Genomic Medicine, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475)
4 University of Alabama at Birmingham, Department of Genetics, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
5 Columbia University, Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
6 Medical University of South Carolina, Department of Pathology and Laboratory Medicine, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475); Medical University of South Carolina, Center for Genomic Medicine, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475); University of Alabama at Birmingham, Department of Pathology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)